FOR IMMEDIATE RELEASE
Contact: John Reher
Executive Director, ABC2
Burlingame, October 28, 2021
Accelerate Brain Cancer Cure (ABC2) Names Young Investigator Awards
BURLINGAME, Calif. - October 28, 2021 - Accelerate Brain Cancer Cure (ABC2), a non-profit foundation dedicated to accelerating therapies leading to a cure for brain cancer, has named three outstanding young investigators in the field of brain cancer research for the inaugural "ABC2 Young Investigator Awards." The three physician/scientist awardees are: Duane Mitchell, M.D., Ph.D., Duke University Medical Center; Viviane Tabar, M.D., Memorial Sloan-Kettering Cancer Center; and Zhiliang Wang, M.D., Ph.D., The Burnham Institute.
"After much consideration and deliberation by our team of reviewers, I am pleased to announce the 2003 Young Investigator awardees, drawn from a pool of highly qualified applicants," stated John Reher, ABC2 Executive Director. "Our 2003 awardees are all excellent researchers with respect to their professional training and their projects are promising, exciting, and fit well within the scope of the ABC2 focus. Additionally, these three physician/scientists work in laboratories at excellent institutions and are guided by mentors who provide outstanding direction to further their careers in the field of brain cancer."
Each ABC2 "Young Investigator Award" provides $150,000 over the course of three years and is intended to encourage motivated young physician/scientists to pursue a career and research in the field of neuro-oncology. The three awardees are involved in distinct areas of brain tumor research. Dr. Mitchell is developing a dendritic cell vaccine for high-grade malignant astrocytomas that targets cytomegalovirus antigens recently discovered to be present within gliomas. Dr. Tabar is studying a subpopulation of cancer cells within brain tumors that may be responsible for the initiation and maintenance of tumor growth and whose characterization may lead to the development of more targeted therapeutic strategies. Dr. Wang's research is focused on developing small-molecule therapeutics for glioblastoma that work by breaking down the cancer cell's ability to override programmed cell death.
ABC2 was founded in May 2001 by Dan and Steve Case and their families, along with leading scientists and entrepreneurs. ABC2 aims to raise awareness about brain cancer and help mobilize critical scientific research through research grants and partnerships. As a 501(c)(3) tax-exempt, non-profit foundation, ABC2 funds outstanding and novel translational science that is aimed at the discovery of a cure for brain cancer.
Each year more than 17,000 people in the United States find out that they have a primary brain tumor. An additional 100,000 patients are diagnosed with a brain tumor that has metastasized from another part of the body. The mission of ABC2 is to accelerate a cure for brain cancer by increasing the number of potential therapies discovered and then rapidly moving them into the clinic to help patients. In order to accelerate progress in what has been an under-served field of research, ABC2 provides researchers from all backgrounds with the support they need to make critical breakthroughs in brain cancer research. Further information can be found at: www.abc2.org.
# # #